Adtalem Global Education (NYSE:CVSA) CFO Robert Phelan Sells 2,900 Shares

Adtalem Global Education Inc. (NYSE:CVSA) CFO Robert Phelan sold 2,900 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $135.41, for a total value of $392,689.00. Following the completion of the sale, the chief financial officer directly owned 52,906 shares of the company’s stock, valued at $7,164,001.46. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adtalem Global Education Stock Performance

CVSA stock opened at $131.17 on Friday. The business’s 50 day moving average price is $124.40. The firm has a market cap of $4.46 billion, a P/E ratio of 20.43, a P/E/G ratio of 0.99 and a beta of 0.62. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.36. Adtalem Global Education Inc. has a fifty-two week low of $86.97 and a fifty-two week high of $156.26.

Adtalem Global Education (NYSE:CVSA) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.73 by $0.25. The firm had revenue of $487.03 million during the quarter. Adtalem Global Education had a return on equity of 20.19% and a net margin of 12.26%.The company’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the business posted $1.92 EPS. Adtalem Global Education has set its FY 2026 guidance at 7.950-8.150 EPS. Equities analysts predict that Adtalem Global Education Inc. will post 8.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CVSA. Truist Financial boosted their price target on shares of Adtalem Global Education from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Zacks Research lowered shares of Adtalem Global Education from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Adtalem Global Education in a report on Friday, May 22nd. Barrington Research reissued an “outperform” rating and set a $170.00 target price on shares of Adtalem Global Education in a research report on Monday, June 8th. Finally, Wall Street Zen upgraded shares of Adtalem Global Education from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $155.00.

About Adtalem Global Education

Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.